Dr Lal Pathlabs Ltd
Dr Lal Pathlabs Ltd Share Price Today: Live Updates & Key Insights
Get insights on Dr Lal Pathlabs Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.
Dr Lal Pathlabs Ltd Share Price Chart
Dr Lal Pathlabs Ltd Fundamentals
Traded Volume: 98,610
Market Cap(Cr): 26,324
Avg Traded Price 3127.82
1 Year return 3.84%
Upper Circuit 3,165.5
Lower Circuit 3,083
P/E TTM 49.00
P/B Ratio 64.00
Traded Value(Cr) 3098.52
EPS TTM 63.801
Book value 63.801
Dividend 1.00%
Dr Lal Pathlabs Ltd Share Price Performance
Shows the percentage change in stock price over different time periods
This section highlights Dr Lal Pathlabs Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Dr Lal Pathlabs Ltd share price history, short-term movements, long-term trends, and overall investor sentiment
1W -0.04%
1M -0.16%
3M -8.95%
1Y +3.84%
YTD +2.44%
Dr Lal Pathlabs Ltd Traded Volume Movement
Shows the trading volume over different time periods
This section highlights Dr Lal Pathlabs Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment
Yesterday 1.51L
Day Before Yesterday 3.08L
1W Avg 1.35L
1M Avg 1.42L
3M Avg 1.37L
Dr Lal Pathlabs Ltd Technical Details
Dr Lal Pathlabs Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.
Support 1 3095
Support 2 3048
Support 3 3012
Pivot Point : 3130
Resistance 1 3177
Resistance 2 3213
Resistance 3 3260
Dr Lal Pathlabs Ltd Corporate Actions
Dr Lal Pathlabs Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Dr Lal Pathlabs Ltd’s capital allocation strategies.
All
Ex-Date 07-Nov-2025 Type D Description 7.00/share@70.00% Record Date 07-Nov-2025 Ratio 70.00
Ex-Date 06-Aug-2025 Type D Description 6.00/share@60.00% Record Date 06-Aug-2025 Ratio 60.00
Ex-Date 06-Jun-2025 Type D Description 6.00/share@60.00% Record Date 06-Jun-2025 Ratio 60.00
Ex-Date 05-Feb-2025 Type D Description 6.00/share@60.00% Record Date 05-Feb-2025 Ratio 60.00
Ex-Date 05-Nov-2024 Type D Description 6.00/share@60.00% Record Date 05-Nov-2024 Ratio 60.00
Ex-Date 20-Aug-2024 Type D Description 6.00/share@60.00% Record Date 20-Aug-2024 Ratio 60.00
Ex-Date 10-Jun-2024 Type D Description 6.00/share@60.00% Record Date 10-Jun-2024 Ratio 60.00
Ex-Date 13-Feb-2024 Type D Description 12.00/share@120.00% Record Date 13-Feb-2024 Ratio 120.00
Ex-Date 11-Aug-2023 Type D Description 6.00/share@60.00% Record Date 11-Aug-2023 Ratio 60.00
Ex-Date 11-Aug-2023 Type D Description 6.00/share@60.00% Record Date 11-Aug-2023 Ratio 60.00
Ex-Date 05-Aug-2022 Type D Description 6.00/share@60.00% Record Date 09-Aug-2022 Ratio 60.00
Ex-Date 22-Jun-2022 Type D Description 6.00/share@60.00% Record Date 23-Jun-2022 Ratio 60.00
Ex-Date 18-Aug-2021 Type D Description 6.00/share@60.00% Record Date 22-Aug-2021 Ratio 60.00
Ex-Date 20-Jul-2021 Type D Description 8.00/share@80.00% Record Date 22-Jul-2021 Ratio 80.00
Ex-Date 09-Feb-2021 Type D Description 6.00/share@60.00% Record Date 10-Feb-2021 Ratio 60.00
Ex-Date 18-Nov-2020 Type D Description 6.00/share@60.00% Record Date 19-Nov-2020 Ratio 60.00
Ex-Date 05-Mar-2020 Type D Description 6.00/share@60.00% Record Date 06-Mar-2020 Ratio 60.00
Ex-Date 20-Nov-2019 Type D Description 6.00/share@60.00% Record Date 21-Nov-2019 Ratio 60.00
Ex-Date 02-Aug-2019 Type D Description 3.50/share@35.00% Record Date - Ratio 35.00
Ex-Date 19-Nov-2018 Type D Description 2.50/share@25.00% Record Date 20-Nov-2018 Ratio 25.00
Ex-Date 03-Aug-2018 Type D Description 3.00/share@30.00% Record Date - Ratio 30.00
Ex-Date 20-Nov-2017 Type D Description 1.50/share@15.00% Record Date 21-Nov-2017 Ratio 15.00
Ex-Date 12-Jul-2017 Type D Description 1.70/share@17.00% Record Date - Ratio 17.00
Ex-Date 13-Feb-2017 Type D Description 1.30/share@13.00% Record Date 14-Feb-2017 Ratio 13.00
Ex-Date 20-Jul-2016 Type D Description 2.45/share@24.50% Record Date - Ratio 24.50
Dividends
Announcement Date 07-Nov-2025 Ex Dividend Date 07-Nov-2025 Dividend(%) 70
Announcement Date 06-Aug-2025 Ex Dividend Date 06-Aug-2025 Dividend(%) 60
Announcement Date 06-Jun-2025 Ex Dividend Date 06-Jun-2025 Dividend(%) 60
Announcement Date 05-Feb-2025 Ex Dividend Date 05-Feb-2025 Dividend(%) 60
Announcement Date 05-Nov-2024 Ex Dividend Date 05-Nov-2024 Dividend(%) 60
Announcement Date 20-Aug-2024 Ex Dividend Date 20-Aug-2024 Dividend(%) 60
Announcement Date 10-Jun-2024 Ex Dividend Date 10-Jun-2024 Dividend(%) 60
Announcement Date 13-Feb-2024 Ex Dividend Date 13-Feb-2024 Dividend(%) 120
Announcement Date 11-Aug-2023 Ex Dividend Date 11-Aug-2023 Dividend(%) 60
Announcement Date 11-Aug-2023 Ex Dividend Date 11-Aug-2023 Dividend(%) 60
Announcement Date 05-Aug-2022 Ex Dividend Date 05-Aug-2022 Dividend(%) 60
Announcement Date 22-Jun-2022 Ex Dividend Date 22-Jun-2022 Dividend(%) 60
Announcement Date 18-Aug-2021 Ex Dividend Date 18-Aug-2021 Dividend(%) 60
Announcement Date 20-Jul-2021 Ex Dividend Date 20-Jul-2021 Dividend(%) 80
Announcement Date 09-Feb-2021 Ex Dividend Date 09-Feb-2021 Dividend(%) 60
Announcement Date 18-Nov-2020 Ex Dividend Date 18-Nov-2020 Dividend(%) 60
Announcement Date 05-Mar-2020 Ex Dividend Date 05-Mar-2020 Dividend(%) 60
Announcement Date 20-Nov-2019 Ex Dividend Date 20-Nov-2019 Dividend(%) 60
Announcement Date 02-Aug-2019 Ex Dividend Date 02-Aug-2019 Dividend(%) 35
Announcement Date 19-Nov-2018 Ex Dividend Date 19-Nov-2018 Dividend(%) 25
Announcement Date 03-Aug-2018 Ex Dividend Date 03-Aug-2018 Dividend(%) 30
Announcement Date 20-Nov-2017 Ex Dividend Date 20-Nov-2017 Dividend(%) 15
Announcement Date 12-Jul-2017 Ex Dividend Date 12-Jul-2017 Dividend(%) 17
Announcement Date 13-Feb-2017 Ex Dividend Date 13-Feb-2017 Dividend(%) 13
Announcement Date 20-Jul-2016 Ex Dividend Date 20-Jul-2016 Dividend(%) 25
Bonus
No Bonus has been declared by LALPATHLAB
Splits
No Split has been declared by LALPATHLAB
Others
Rights No Rights has been declared by LALPATHLAB
Dr Lal Pathlabs Ltd Peer Comparison
Shows key financial metrics for the company and its peers
This section compares Dr Lal Pathlabs Ltd with leading peers in the banking sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Dr Lal Pathlabs Ltd's relative performance and valuation against major competitors.
Stock Name Inventurus Knowledge Solutions Ltd ₹1568.00 (-1.41%) M. Cap (Cr) 269.17 1 Yr Return (%) NaN% P/E (TTM) 44.12 PB Ratio 23.23
Stock Name Dr Lal Pathlabs Ltd ₹3142.20 (+0.47%) M. Cap (Cr) 263.24 1 Yr Return (%) +3.84% P/E (TTM) 49.25 PB Ratio 13.15
Stock Name Indegene Ltd ₹510.05 (-0.98%) M. Cap (Cr) 122.48 1 Yr Return (%) -20.42% P/E (TTM) 27.47 PB Ratio 5.19
Stock Name Vijaya Diagnostic Centre Ltd ₹1007.40 (-0.40%) M. Cap (Cr) 103.49 1 Yr Return (%) -12.24% P/E (TTM) 68.35 PB Ratio 14.28
Stock Name Metropolis Healthcare Ltd ₹1955.10 (-0.22%) M. Cap (Cr) 101.32 1 Yr Return (%) -3.01% P/E (TTM) 64.03 PB Ratio 8.56
Stock Name Thyrocare Technologies Ltd ₹1535.20 (+0.66%) M. Cap (Cr) 81.45 1 Yr Return (%) +58.32% P/E (TTM) 63.77 PB Ratio 16.68
Stock Name Kovai Medical Center & Hospital Ltd ₹2576.65 (-2.28%) M. Cap (Cr) 28.19 1 Yr Return (%) +68.20% P/E (TTM) 28.66 PB Ratio 6.03
Dr Lal Pathlabs Ltd Cash Flow
Cash flow data provides a view of how money is generated and spent by Dr Lal Pathlabs Ltd, across its operating activities, investing activities, and financing activities.
PARTICULARS Operating Activities Mar 2025 540.00 Mar 2024 477.60 Mar 2023 427.53 Mar 2022 423.81 Mar 2021 373.36
PARTICULARS Investing Activities Mar 2025 -293.00 Mar 2024 31.91 Mar 2023 -288.47 Mar 2022 -448.50 Mar 2021 -195.19
PARTICULARS Financing Activities Mar 2025 -324.75 Mar 2024 -404.00 Mar 2023 -270.05 Mar 2022 142.04 Mar 2021 -135.74
PARTICULARS Net Cash Flow Mar 2025 -77.75 Mar 2024 105.51 Mar 2023 -130.99 Mar 2022 117.34 Mar 2021 42.42
Dr Lal Pathlabs Ltd Shareholding Pattern
This shows the ownership breakdown of Dr Lal Pathlabs Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.
Promoter 53.21%
Public 6.07%
Other Institutions 2.59%
FII 21.86%
Mutual Funds 15.9%
About Dr Lal Pathlabs Ltd
Dr. Lal PathLabs Limited was incorporated as a Private Limited Company with the name `Dr. Lal PathLabs Private Limited', on February 14, 1995 at Delhi. The business of the Partnership Firm, Central Clinical Laboratory was undertaken by the Company. The Company converted into a Public Limited Company and name of the Company was changed to `Dr. Lal PathLabs Limited' vide fresh Certificate of Incorporation granted by the RoC on August 19, 2015.Dr Lal PathLabs is among the most trusted diagnostic healthcare service provider in India, offering services through over 5000 diagnostic tests and related healthcare services through a nationwide network of medical laboratory centres. Through its integrated, nationwide network, the Company offers patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.Presently, the Company is engaged the business of running laboratories for carrying out pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immunochemistry, immunology, virology, cytology, and other pathological and radiological investigations. The Company has built a national, 'hub and spoke' network that includes its National Reference Laboratory in New Delhi, Regional Reference Lab in Kolkata and 371 other clinical laboratories, 5,102 patient service centers and 10,938 pickup points as of 31 March 2023. Its customers include individual patients, hospitals and other healthcare providers and corporate customers. Apart from these, the catalogue of services includes 481 test panels, 2763 pathology tests and 1947 radiology and cardiology tests.Late Dr. Major S.K. Lal, commenced the business of providing pathology services and maintaining a blood bank in the year 1949 through sole proprietorship M/s. Central Clinical Laboratory and M/s. Blood Bank Transfusion Centre. The business of diagnostic and related healthcare tests and services now continues to be provided by the Company 'Dr Lal Pathlabs Pvt. Ltd.'The Board of Directors of Dr. Lal PathLabs at its meeting held on 12 May 2017 approved the Scheme of Amalgamation of Delta Ria and Pathology Private Limited, a wholly owned subsidiary of the Company with the Company with effect from 1 April 2017. The Scheme was sanctioned by the New Delhi and Ahmedabad Bench of Hon'ble National Company Law Tribunal (NCLT), on October 23, 2018 and December 11, 2018 respectively. Pursuant thereto, in accordance with the terms of the scheme, Delta Ria And Pathology Private Limited was amalgamated with Dr. Lal PathLabs Limited w.e.f. April 1, 2017. The Board of Directors of Dr. Lal PathLabs at its meeting held on 7 August 2017 approved acquisition of 70% stake in Dr. Lal Path Labs Bangladesh (Pvt) Limited (DLPLB) from existing shareholders. Prior to investment in the company by Dr. Lal PathLabs, DLPLB shall be acquiring the running diagnostic business of a sole-proprietorship firm in Dhaka, Bangladesh. On 12 December 2017, Dr. Lal PathLabs announced that the Board of Directors of the company's subsidiary Paliwal Diagnostics Private Limited, at its meeting held on 12 December 2017 approved acquisition of a proprietary concern viz. Satya Pathology and Diagnostic Centre (SPDC) based out of Kanpur. SPDC clocked turnover of Rs 1.46 crore in FY 2017.Dr. Lal PathLabs' Kolkata Reference Lab started testing of samples in early January 2018. The World-class Lab will cater the demand from Northeast as well as Eastern regions of India. It will also cater to neighboring international arena. During the FY2019, Dr. Lal Ventures Private Limited and PathLabs Unifiers Private Limited were incorporated on December 10 and December 12, 2018, respectively, as wholly owned subsidiaries of the Company. As on 31 March 2019,the company has 5 domestic and 3 overseas subsidiaries under its roof.The Board of Directors of your Company in their meeting held on February 3, 2020, approved a Scheme of Amalgamation (the Scheme) between the Company and APL Institute of Clinical Laboratory & Research Private Limited, a wholly owned subsidiary of the Company. The Company is in the process of filing a petition Application before the National Company Law Tribunal, New Delhi for approval of the Scheme of Amalgamation.During the FY2020, Company's Wholly Owned Subsidiary viz M/s. PathLabs Unifiers Private Limited acquired 70% equity stake in M/s Centrapath Labs Private Limited and M/s. APRL PathLabs Private Limited consequent upon which both these Companies became subsidiaries of the Company. Also Dr. Lal PathLabs Kenya Private Limited was incorporated on August 6, 2019, as a Wholly Owned Subsidiary of the Company in Kenya. The Company has subscribed to equity share capital amounting to KES 10 million (Rs 7.10 million) consisting of 9,880 shares of KES 100.As on 31 March 2020,the company has 7 domestic and 4 overseas subsidiaries under its roof.During the year 2019-20, the Company has made a further investment of Rs 599.00 million and Rs 9.00 million in this subsidiary Company Pathlabs Unifiers Private Limited and Dr. Lal Ventures Private Limited respectively through subscription of additional shares. During the quarter ended 30 June 2020,the company has made a further investment of Rs 15 million in its whollyowned subsidiary Pathlabs Unifiers Private Ltd,through subscription of additional equity shares.Subsequent to the quarter ended 30 September 2020,pursuant to approval of the Board of Directors of Pathlabs Unifiers Private Ltd(PUPL),a wholly owned subsidiary,PUPL has signed binding term sheets on 06 November 2020,for the acquisition of the business of Bindish Diagnostic Laboratory LLP, Gujarat,on a going concern basis,for a purchase consideration not exceeding Rs 40 million and equity stake of 40% in ChanRe Diagnostic Services Private Ltd,Bengaluru,for a purchase consideration not exceeding Rs 175 million. Both of these companies are engaged in providing pathological diagnostic services.During year 2020-21, the Company added 15 labs, 600 collection center and 2200 pick-up points. It had overall 231 clinical labs, 3,705 patient service centres and 9,247 pickup-up points as on March 31, 2021.The Board of Directors of the Company in their meeting on February 3, 2020, approved a Scheme of Amalgamation between Dr. Lal PathLabs Limited (the Transferee Company) and APL Institute of Clinical Laboratory & Research Private Limited, a wholly owned subsidiary of the Company (Transferor Company), which was sanctioned on May 13, 2022 and the appointed date for the Scheme is April 1, 2020.During the year 2021-22, the Company acquired 100% stake in M/s Suburban Diagnostics (India) Private Limited and consequently, Suburban became a Wholly Owned Subsidiary of the Company, effective November 12, 2021. It introduced 46 labs, 1,026 patient service centers and 1,352 pick-up points.The Company opened its Reference Lab at Vidyavihar, in Mumbai in Jan' 23. Dr. Lal PathLabs expanded its National Reference Lab in Rohini, Delhi, by acquiring a second electron microscope, an upgraded lab information system and advanced tools such as artificial intelligence and data mining.During FY 2023, the Company operated a network of 277 clinical labs, including the prestigious National Reference Lab in Delhi and the Regional Reference Lab in Kolkata, Bangalore and Mumbai. Additionally, with 5,102 Patient Service Centres (PSCs) and 10,938 Pick-up Points (PUPs), the Company has established a nationwide presence. APL Institute of Clinical Laboratory & Research Private Limited, a wholly owned subsidiary of Company (APL/ Transferor Company), was amalgamated with Dr. Lal PathLabs Limited (the Company/ Transferee Company) effective on March 27, 2023. The Company launched 134 tests in FY' 23 to expand the Super Specialty Portfolio.In 2024, Company introduced the pioneering Histocompatibility and Transplant Immunology testing with Next Generation Sequencing (NGS), which facilitated over 600 runs of HLA-NGS, for analysing 27,000 samples of Bone Marrow and Solid Organ Transplantationin India, Africa, Bangladesh and Nepal. It also established the `donor-derived cell-free DNA' as a non-invasive monitoring test for solid organ transplantation .In 2025, Company has launched multiple Center of Excellence in recent times focusing on various specialities such as Genevolve (Genetic Testing ), L-ACE(Autoimmunity), L-CoRD (Reproductive Diagnosis) & L-CID (Infectious Diseases) defining the steps towards Medical Excellence. The Company has expanded its test offering which include basic preventive health packages SwasthFit to most advanced investigations such as Comprehensive Genomic Profile, Myeloid testing for Haematological Malignancies & Amyloid Typing Solutions. The Company is actively working to Introduce the Artificial Intelligence based algorithm in multiple diagnostics areas suchas Histopath & Haematology to improve the efficiency, accuracy and reproducibility of results.
Executive Chairman
Arvind Lal
Registered office E-2 Block Sector 18, Rohini, New Delhi, New Delhi, 110085
FAX :91-011-3024 4149
Background
Incorporation Year 1995
Face Value ₹10.00
Market Lot 1
FAQs on Dr Lal Pathlabs Ltd
How to buy Dr Lal Pathlabs Ltd shares on NSE?
To buy Dr Lal Pathlabs Ltd shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified.
What is the Dr Lal Pathlabs Ltd share price today?
The Dr Lal Pathlabs Ltd share price on NSE is ₹3142.20 today.
What is the market cap of Dr Lal Pathlabs Ltd on NSE?
The company has a market capitalization of ₹26323.94.
What is the PE & PB ratio of Dr Lal Pathlabs Ltd?
PE is 49 and PB is 64.
What is the 52 Week High and Low of Dr Lal Pathlabs Ltd shares?
Dr Lal Pathlabs Ltd stock price high: ₹3540 Dr Lal Pathlabs Ltd stock price low: ₹2293.55.